About deCODE Genetics
deCODE Genetics is a company based in Reykjavik (Iceland) founded in 1996 was acquired by Amgen in December 2012. deCODE Genetics has completed 1 acquisition, including UVS. deCODE Genetics offers products and services including Genome Analysis Platform and AI Splicing Prediction Tool. deCODE Genetics operates in a competitive market with competitors including Novogene Corporation, Rejuvenate Bio, Source BioScience, Beikang Medical and Macrogen, among others.
- Headquarter Reykjavik, Iceland
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of deCODE Genetics
deCODE Genetics offers a comprehensive portfolio of products and services, including Genome Analysis Platform and AI Splicing Prediction Tool.
Platform for identifying genetic variations linked to human diseases
Method to enhance accuracy of RNA splicing predictions in genetics
People of deCODE Genetics
Unlock access to complete
Funding Insights of deCODE Genetics
Investors in deCODE Genetics
deCODE Genetics has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Amgen, HHS and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked | |
|
Developer of pharmaceutical products for treating multiple diseases
|
Locked | Locked | Locked |
Investor details for deCODE Genetics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by deCODE Genetics
deCODE Genetics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include UVS.
Investment portfolio details for deCODE Genetics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Cancer research is conducted via population genomic studies.
|
Locked | Locked | 1999 | Locked |
Complete acquisition details for deCODE Genetics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - deCODE Genetics
Detailed financials for deCODE Genetics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Decode Genetics Comparisons
Peer comparison for deCODE Genetics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of deCODE Genetics
deCODE Genetics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Novogene Corporation, Rejuvenate Bio, Source BioScience, Beikang Medical and Macrogen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Genomic services and solutions with NGS expertise are provided.
|
|
| Locked | Locked | Locked |
Gene-editing platform and anti-aging therapy for dogs are developed.
|
|
| Locked | Locked | Locked |
Multiple genomic services are provided for analysis and diagnostics.
|
|
| Locked | Locked | Locked |
NGS-based diagnostic solutions for neonatal screening are developed.
|
|
| Locked | Locked | Locked |
Next-generation sequencing and genomics services are provided globally.
|
|
| Locked | Locked | Locked |
Genome sequencing, analysis, and genetic screening services are provided.
|
Detailed competitors of deCODE Genetics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Decode Genetics
Complete news archive for deCODE Genetics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about deCODE Genetics
deCODE Genetics was founded in 1996 and raised its 1st funding round 11 years after it was founded.
deCODE Genetics is headquartered in Reykjavik, Iceland.
Founded in 1996 in Reykjavik, Iceland, operations in the bioinformatics sector are conducted by deCODE Genetics. Genetic variations linked to diseases including cardiovascular, psychiatric, and cancer conditions are identified through a platform supported by extensive genotypic and medical data from 160,000 Icelandic volunteers. A genealogical database spanning nearly 1,000 years is maintained, facilitating large-scale disease studies with minimized bias and genotype imputation capabilities.
deCODE Genetics's top competitors include Novogene Corporation, Source BioScience and Genewiz.
deCODE Genetics offers Genome Analysis Platform and AI Splicing Prediction Tool.
deCODE Genetics has made 1 acquisition, including UVS.
deCODE Genetics has 3 investors. Key investors include Amgen, HHS, and European Union.